Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTPa-IPV · 1 trial · 3 indications
A seroprotected subject was defined as a vaccinated subject with anti-diphteria (anti-D) and anti-tetanus (anti-T) antibody concentrations greater than or equal to (≥) the cut-off value of 0.1 international units/milliliter (IU//mL).
A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 (Anti-Polio 1, 2 and 3) antibody titers greater than or equal to (≥) the cut-off value of 8.
Vaccine response was defined as: - for initially seronegative subjects, antibody concentrations ≥ 5 EL.U/mL one month after third vaccine dose; - for initially seropositive subjects, at least maintenance of pre-vaccination antibody concentrations one month after third vaccine dose.
Vaccine response to pertussis toxoid (PT), pertactin (PRN) and filamentous haemagglutinin (FHA) was defined as the appearance of antibodies in subjects who were initially (i.e. before vaccination) seronegative (i.e. with concentrations \< 5 EL.U/mL), or at least as the maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e. with concentrations ≥ 5 EL.U/mL value).
| Arm | Type | Description |
|---|---|---|
| Infanrix-IPV Group | EXPERIMENTAL | Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh. |
| Infanrix + IMOVAX Polio Group | ACTIVE_COMPARATOR | Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs. |
| Name | Type | Description |
|---|---|---|
| DTPa-IPV | BIOLOGICAL | 3 intramuscular injections |
| DTPa | BIOLOGICAL | 3 intramuscular injections |
| IMOVAX Polio® | BIOLOGICAL | 3 intramuscular injections |
Inclusion criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol . * A male or female between, and including, 8 and 12 weeks (56-90 days) of age at the time of the first vaccination. * Written informed consent obtain...
DTPa-IPV is an investigational vaccine being studied for the prevention of tetanus, as well as acellular pertussis and diphtheria. It is intended for use in healthy infants, with the clinical trial evaluating immunogenicity, safety, and reactogenicity in this population.
DTPa-IPV is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research to evaluate the vaccine's safety and immunogenicity in infants.
DTPa-IPV is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness.
DTPa-IPV has one completed Phase 3 clinical trial, registered as NCT00290342. This study evaluated the immunogenicity, safety, and reactogenicity of the combined DTPa-IPV vaccine in healthy infants, enrolling 458 participants in South Korea.
DTPa-IPV is a combined vaccine that includes components for diphtheria, tetanus, acellular pertussis, and inactivated poliovirus. The clinical trial specifically assessed this combination in healthy infants to evaluate its immune response and safety profile.